Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1749-6632.1982.tb37420.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of first intervention on cardiac parameters in patients with acromegaly: a systematic review.
Eur J Endocrinol
January 2025
Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
Objective: Cardiovascular disease in acromegaly patients remains a major cause of morbidity and all-cause mortality. This systematic review investigates the effect of the first growth hormone lowering intervention on cardiac parameters.
Design: Systematic review.
Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism.
Int J Mol Sci
January 2025
Endocrinology Unit, Department of Internal Medicine and Medical Specialties, School of Medical and Pharmaceutical Sciences, University of Genova, 16132 Genova, Italy.
Acromegaly is a rare endocrine disorder caused by excessive growth hormone (GH) production, due, in the vast majority of cases, to the presence of a GH-secreting pituitary tumour. The chronic elevation of GH and the resulting high circulating levels of insulin-like growth factor-1 (IGF-1) cause the characteristic tissue overgrowth and a number of associated comorbidities, including several metabolic changes, such as glucose intolerance and overt diabetes mellitus (DM). Elevated GH concentrations directly attenuate insulin signalling and stimulate lipolysis, decreasing glucose uptake in peripheral tissues, thus leading to the development of impaired glucose tolerance and DM.
View Article and Find Full Text PDFCase report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy.
Front Oncol
January 2025
Department of Nuclear Medicine, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United States.
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapies who achieved symptomatic control and a significant decrease in serum VIP levels with PRRT during their hospital stay. Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy.
View Article and Find Full Text PDFLong-range inputome of prefrontal GABAergic interneurons in the Alzheimer's disease mouse.
Alzheimers Dement
January 2025
Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Sanya, China.
Introduction: Alzheimer's disease (AD) is the most common neurodegenerative disease, characterized by damage to cortical circuits. However, the mechanisms underlying AD-associated changes in long-range circuits remain poorly understood.
Methods: In this study, we used viral tracing and fluorescence micro-optical sectioning tomography (fMOST) imaging to investigate whole-brain changes in the input circuit of the frontal cortex of 5×FAD mice.
Managing Chyle Leakage Following Right Retroperitoneoscopic Adrenalectomy: A Case Study.
Am J Case Rep
January 2025
Department of Urology, Liaocheng Second People's Hospital, Liaocheng, Shandong, China.
BACKGROUND Surgery involving the right retroperitoneum can result in lymphatic (chylous) leakage from the cisterna chyli located anterior to the L1 and L2 vertebra or from lymph node dissection. This report describes a 46-year-old woman with retroperitoneal lymphatic (chylous) leak following right adrenalectomy for a nonfunctional adrenal adenoma. CASE REPORT A 46-year-old woman presented with a medical history of hypertension.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!